News

Research helix biopharma pioneer in cancer therapy targeting tumor microenvironment tme

Health
0 min read

Wednesday, February 12, 2020

Helix Biopharma (HBP: CA)

Pioneer in Cancer Therapy Targeting Tumor Microenvironment (TME)

Helix BioPharma Corp is a Canada-based clinical-stage biopharmaceutical company focused on cancer drug development. It develops therapies in the field of immuno-oncology based on its proprietary technology mainly in the areas of cancer prevention and treatment. The company has Tumor Defense Breakers (L-DOS47), and Tumor Attackers (CAR-T) product candidates in the pipeline.

Cosme Ordonez, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Unique Technology Targeting Tumor Microenvironment (TME). We view Helix Biopharma as a pioneer in the cancer area as the company is developing a platform technology targeting the tumor microenvironment. Helix’s technology is designed to reduce tumor acidity, an escape mechanism which cancer cells utilize to evade the anti-tumor immune response. Tumor acidity has been shown to correlate with resistance to anti-cancer treatment and poor prognosis for cancer patients.

Lead drug L-DOS47 for the Treatment of Cancer. Helix Biopharma’s lead drug, L-DOS47, is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. In a clinical trial using L-DOS47 as a mono-therapy for the treatment of NSCLC, treated patients showed reductions in tumor size and…


Get the full report on Channelchek desktop.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in the full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

Share

Inbox Intel from Channelchek.

Informed investors make more money. And it’s all about timing. Get it when it happens.

By clicking submit you are agreeing to the Terms of Use and Privacy Policy
© 2018-2024 Noble Financial Group, Inc. All Rights Reserved. Channelchek is provided at no cost to be used for information purposes only and not as investment advisement.